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African Animal Trypanosomiasis is a disease that primarily afflicts cattle in Africa. It affects 
at least 37 countries in the region and, in 2017, was estimated to be responsible for the 
overall loss of around £4.75 billion per annum to the rural economy. The various 
symptoms, ultimately leading to the deaths of over 3 million cattle per year, result in a 
reduction of every aspect of livestock farming and it is therefore considered a severe 
repressor of central African development both cultural and economic. 
 
It is caused by the group of parasitic protozoa called Trypanosoma, which are carried by 
all flies of the ‘Glossina’ genus (tsetse flies) and renders large swathes of rural Africa – 
particularly the ‘tsetse belt’ – unsuitable for cattle farming. The two organisms most 
significant in causing this widespread economic repression are Trypanosoma congolense 
and Trypanosome vivax. Aminoacyl tRNA synthetase enzymes have been previously 
identified as promising potential drug targets in T. congolense and, in this study, that 
potential is being explored through the generation of crystal structures of those enzymes. 
 
Three structures of T. congolense lysyl-tRNA Synthetase I (LysRS1) have been solved 
following expression in Rosetta 2 pLacI E. coli cells and purification using cobalt affinity 
chromatography and size exclusion chromatography. The structures contain LysRS1 
complexed with lysine and AMP (LAM_G4; 1.9 Å), with the lysyl-AMP intermediate 
(LAM_H2; 2.2 Å) and with the nucleoside analogue cordycepin (LCM_F3; 2.4 Å). These 
structures provide a detailed description of the T. congolense LysRS1 active site and 
comparing these structures with mammalian LysRS enables identification of differences in 
the ATP-binding site that could be exploited in structure-based drug-design. Furthermore, 
conformational changes in a pair of loops associated with the active site may be significant 
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In an individual animal, African Animal Trypanosomiasis (AAT or Nagana, from the Zulu word 
"N'gana" meaning "powerless/useless") causes symptoms such as anaemia and emaciation, and 
without treatment can often lead to death. (Muhanguzi et al., 2014) At the herd level it leads to 
lower fertility rates, stunted growth, lower milk yields and a higher overall mortality rate, especially 
of infants. From meat and milk production to draft power, Nagana is therefore said to cause a 
reduction in every aspect of livestock farming such that it can be considered one of the industry's 
biggest constraints (Holt et al., 2016). Both it and the closely related Human African 
Trypanosomiasis (HAT) are considered to have historically caused severe repression of Central 
African cultural and economic development (Steverding, 2008). Due to the close relationship 
between the Nagana-causing species Trypanosoma brucei brucei and its two other subspecies 
(Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense) that cause HAT, there is 
potential for zoonosis and, in fact, warnings already exist from the Center for Food Security and 
Public Health in 2009 that non-zoonotic trypanosomes may cause disease in humans with certain 
genetic defects. Despite all of this, Nagana has seen relatively little pharmaceutical attention when 
compared to HAT, and so this investigation intends to extend a previous study further exploring the 
potential of inhibition-based drugs for the treatment of AAT. Ultimately, the hope is that the 




Nagana is the result of infection by members of a group of unicellular parasitic protozoa called 
Trypanosoma, specifically by organisms Trypanosoma congolense, Trypanosoma vivax and the 
brucei subspecies of Trypanosoma brucei (Morrison et al., 2016). The genus was named for its 
characteristic drill-like motion by David Gruby who, whilst studying a parasitic organism in frog 
blood in 1843, described its movement as "...like a drill or corkscrew, which is why I propose to 
name this hematozoan 'Trypanosoma'." - from the Greek words 'Trypanon' (auger) and 'Soma' 
(body) (Langousis & Hill, 2014). The large, biting flies that carry them are unique to Africa and feed 
on the blood of vertebrate mammals. T. vivax also exists in South America where several types of 
biting fly transmit it, in contrast to in Africa where tsetse flies are the exclusive vector (Jones and 









Figure 1: Distribution of T. vivax and T. congolense. 
This image shows the distribution of the two main causes of Nagana 





















The trypanosome lifecycle can be said to begin when a tsetse fly bites and ingests the blood of an 
infected mammal, after which the parasite then undergoes a developmental cycle involving 
proliferation, migration and ultimately differentiation into an infectious form, ripe for transfer to their 
next mammalian host (Rotureau and Van Den Abbeele, 2013). Many studies simplify these 
parasites’ life cycles as consisting of only two stages – in mammalian blood and in the fly vector – 































However, in reality it is much more complicated: the trypanosomes have a multitude of different 
morphological forms, corresponding to different stages of their developmental cycle corresponding 
with different locations within their host or vector (Matthews, 2005). The metabolism of the 
trypanosome differs depending on its morphological form. For example, energy production is 
achieved through proline oxidation and oxidative phosphorylation when in the midgut stage 
compared to a total reliance on glycolysis and substrate-level phosphorylation in the bloodstream 
form (Eyford et al., 2011). In the fly salivary gland stage, genes are activated that produce a coat of 
variable surface glycoproteins. This antigen variation mechanism allows trypanosomes to evade 
neutralisation by the immune system of the mammalian host and, when the mammalian 
bloodstream form is ingested by a tsetse fly, these genes are inactivated when the parasite returns 
to the fly midgut stage (Horn, 2014). All of these changes contribute to the parasite being near-
impossible to ‘pin down’ by the host immune system. Instead, the hope is to target a process 
present and necessary at all stages of the life cycle: protein synthesis. 
 
Three distinct developmental pathways have been defined, based on how each species of 
trypanosome travels within the alimentary tract of the fly (Rotureau and Van Den Abbeele, 2013). 
T. vivax has a developmental pathway that lasts around three days and is contained within the 
proboscis and cibarium of the fly. Members of the Nannomonas subgenus, e.g. T. congolense, 
develop as they pass through the midgut, foregut and proboscis (Gibson, 2013). All types of T. 
brucei, including those that infect humans, have a developmental cycle that can last up to three 
weeks as they migrate through the midgut, foregut, proboscis and salivary glands. This is 
summarised in Figure 3 below. 
Figure 2: Basic life-cycle of Nagana-causing Trypanosoma species. 
Simplistically, the Nagana-causing Trypanosoma species can be considered to have 
















As members of the kinetoplastea class, trypanosomes have unusual 'kinetoplast' structures: large 
networks of circular DNA called kDNA that are found within the mitochondria of species belonging 
to this class (Lukes et al., 2002). These structures, along with the presence of other unusual 
features such as the glycosome organelle that compartmentalises glycolysis (Michels et al., 2006), 
distinguish a vast evolutionary distance between the intracellular mechanisms of trypanosomes 
and that of their mammalian hosts. This may make it easier to develop specific compounds to 
inhibit the growth of the parasites, with as little interference as possible to the ordinary cells of the 
host, by targeting proteins that reflect these evolutionary differences. 
 
Aminoacyl-tRNA synthetases 
When considering potential avenues into drug development for diseases caused by microbial 
organisms, protein synthesis stands out as a process that has been thoroughly validated as an 
excellent target for disruption (Orelle et al., 2013). There already exists a wide range of 
antimicrobial drugs that function by interfering with protein synthesis at a variety of different stages 
(Wilson, 2009). Protein synthesis is made doubly attractive as a drug target in parasites because 
they are often dependent on enhanced rates of protein synthesis compared to their hosts, in order 
to support their rapid growth, expansion and development within the host. It is therefore 
reasonable to assume that they are particularly sensitive to having these rapid rates reduced or 
even stopped. 
 
Aminoacyl tRNA synthetases have already been shown to be essential for the in vitro survival and 
Figure 3: Trypanosoma in tsetse flies. 
This briefly summarises the movement of the three different types of nagana-causing 
Trypanosoma species within the tsetse fly vector. At each location, the Trypanosoma 
species assume a different morphological form. 
Pr: proboscis, FG: foregut, Pv: proventriculus, PM: peritrophic matrix, MG: midgut, HG: 
hindgut, R: rectum, SG: salivary glands (Rotureau and Van Den Abbeele, 2013). 
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Figure 4: Aminoacyl-tRNA synthetase primary mechanism. 
The appropriate amino acid binds alongside ATP to the enzyme and, with the energy 
provided by the release of inorganic pyrophosphate, an aminoacyl-adenylate is formed. 
The tRNA then binds to the enzyme and is joined to the amino acid via an esterification 
reaction, releasing AMP (Battenberg et al., 2013). 
growth of T. brucei (Kalidas et al., 2014) – a close relative of T. congolense and T. vivax – and are 
already established as drug targets in bacterial species (Nakama et al., 2001). They are ancient 
enzymes that attach an amino acid to its corresponding tRNA through the catalysis of an 
esterification reaction between a specific amino acid, or its precursor, and one of its compatible 
cognate tRNAs to form the 'aminoacyl tRNA' (aa-tRNA) that acts as a substrate in RNA translation. 
This process is referred to as 'charging' or 'loading' and is shown below as Figure 4. 
 
 
Essentially, this is a two-step reaction that can be written as follows: 
 
𝐴𝐴 + 𝐴𝑎𝑅𝑆 + 𝐴𝑇𝑃 ⇌ 𝐴𝑎𝑅𝑆 ∗ 𝐴𝐴 − 𝐴𝑀𝑃 + 𝑃𝑃𝑖 (1) 
 
𝐴𝐴𝑅𝑆 ∗ 𝐴𝑎 − 𝐴𝑀𝑃 + 𝑡𝑅𝑁𝐴 ⇌ Aa − tRNA + AMP + AaRS (2) 
 
After the charging is complete, a ribosome can then transfer the amino acid from the aa-tRNA onto 
a growing peptide as dictated by the genetic code. Aa-tRNA synthetase, in facilitating the formation 
of aa-tRNA, therefore plays an integral role in protein translation. Although this is their main role, 
they have evolved over millennia to host a variety of additional functions in signalling pathways and 
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other metabolic processes (Freist, 1995). There are twenty-four different aminoacyl-tRNA 
synthetases in T. congolense, with some amino acids being charged by several different types of 
the enzyme. For example, there are thought to separate genes for mitochondrial and cytoplasmic 
tryptophanyl-tRNA synthetase, as identified by the presence (or absence) of a mitochondrial 
signalling sequence (McCready-Fallon, 2018).  
 
Structurally, these are multi-domain proteins containing both a catalytic domain and an anticodon 
domain. The catalytic domain facilitates the 'charging' process whereas the anticodon domain 
interacts with the anticodon region on the RNA to ensure the amino acid is being affixed to the 
correct tRNA (Rogers et al., 1994). Incorrect pairings usually involve two amino acids that have 
similar shapes but different properties. Some aminoacyl tRNA synthetases contain a hydrolytic 
'editing' domain, enabling them to cleave incorrect couplings by hydrolysis of the ester linkage. 
(Beuning and Musier-Forsyth, 2000) On the tRNA, the esterification occurs at the hydroxyl group of 
the terminal adenosine nucleotide. There are two classes of aminoacyl tRNA synthetase: class I, 
which aminoacylates at the 2'-hydroxyl and has two highly conserved sequence motifs, and class II 
which aminoacylates at the 3'-hydroxyl and has three highly conserved sequence motifs (Eriani et 
al., 1990) Members of the former are typically monomeric or dimeric, whereas the latter are 
typically dimeric or tetrameric. These classes are believed to have evolved from different ancestors 
via convergent evolution (Pouplana and Schimmel, 2001).  
 
Lysyl-tRNA synthetase has been identified as a class II synthetase in trypanosomes and comes in 
two forms: LysRS1 and LysRS2. Although it has not been experimentally verified in any 
trypanosomes, LysRS1 has an N-terminal extension that, in humans, shows chemokine activity. 
LysRS2 has a C-terminal extension domain that is, in T. brucei, involved in mitochondrial 
localisation. It is for this reason that LysRS2 is believed to be the kinetoplast form, meaning 
LysRS1 should be the cytoplasmic form (McCready-Fallon, 2018). 
 
X-Ray Crystallography  
When discovered in 1895 by W.C. Röntgen, the mysteriously named 'X-rays' were subject to great 
public interest. Intense research into their qualities and potential applications began almost 
immediately in multiple directions (Tubiana, 1996). As early as 1896, physicians were using X-rays 
on patients to image parts of the skeleton and specific organs and in 1897, when J.J. Thomson 
showed that X-rays were able to ionise gas, further study of this quality led to the discovery of 
electrons. In 1913, X-ray crystallography was developed by W.H. Bragg and his son W.L. Bragg. It 
involves the interpretation of the diffraction pattern created when the crystallised form of a pure 
molecular sample is exposed to X-rays (Bragg and Bragg, 1913). Originally limited to simple 
molecules such as salts, the types of molecule on which the technique could be used grew steadily 
over the first half of the twentieth century. The first crystal structure of a biological macromolecule 
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– that of sperm-whale myoglobin – was published by John Kendrew in 1957 with a resolution of 6 
Å, further improved to 2 Å by 1960. In 1980, the double-helix structure of DNA was solved through 
this method (Wing et al., 1980) although it had previously been inferred via fibre diffraction studies 
(also with X-rays). As of February 2018, there have been over 142,000 depositions to the protein 
data bank, the vast majority of which are protein structures determined using X-ray crystallography 
(Berman et al., 2000). This highlights how exponentially the use of this technique has grown. It is 
currently the most commonly used experimental method to obtain a detailed model of a large 
molecule.  
 
A particle is said to have been scattered when it collides with another particle (called the scatterer) 
and the direction of its motion is altered. In a light microscope, an image is compiled by rays of 
light being coherently scattered by the features of an object and entering a lens, which then 
reconstructs an image of the object on the opposite side of the lens. For scattering to be significant 
enough to be detected, the wavelength of the light must be of similar dimension to the object being 
imaged. Visible light (400-700 nm wavelength) thus cannot produce an image of individual atoms 
in protein molecules, where bonded atoms are only about 0.15 nm apart. Electromagnetic radiation 
of this wavelength falls into the X-ray range; X-rays vary in wavelength from 0.01 to 10 nm and 
therefore are scattered by (the electrons from) even the smallest of molecules. (Drenth, 2007) 
Hydrogen atoms in proteins, however, are still hard to resolve – instead, knowledge of bond 
angles, bond lengths and conformational restraints in small molecules can be used to deduce their 
positions, under the assumption that they behave in proteins as they do in those 
molecules (Rhodes, 2000). 
  
Although individual atoms scatter X-rays, two factors would ordinarily prevent the production of a 
focused image of a single molecule. First, current lenses are not capable of focusing X-rays. 
Secondly, most X-rays will pass through a single molecule without colliding with it. The pattern 
from that single molecule is too weak to be detected as it has been produced by the scattering of 
too few photons. Instead, crystals (which contain many millions of identically orientated molecules 
in an ordered array) are used. A regular array of waves is produced when an X-ray beam interferes 
with a regular array of scatterers, and so the crystal acts as an amplifier for the scattering of X-rays 
by the molecules (Wlodawer et al., 2008).  
 
Although this produces stronger, more easily detectable X-rays, the crystal imposes restrictions on 
the scattering pattern and so the original continuous scattering pattern is now subject to the 
phenomenon of diffraction. This means that the pattern, formerly a continuous blur of varied 
intensities over the detector film, is now sampled only at discrete angular positions (‘spots’) on the 
film where Bragg’s law (n=2dsin, where n is an integer, d is the distance between atomic layers 
in the crystal and  is the X-ray angle of incidence) is fulfilled: where constructive interference is at 
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its strongest (Bragg and Bragg, 1913). These spots, called reflections, make up a three-
dimensional lattice on the detector film called the diffraction pattern. The intensity of each reflection 
must be measured, and their index assigned, and their relative phases then derived - the X-ray 
detector can record the intensities, but not the phases, of the X-rays. The phase of an X-ray 
contains information that is vital to the determination of electron density distribution in the crystal 
and so the loss of this crucial data during the process is known as the ‘phase problem’ (Taylor, 
2003). Deriving the relative phases of the reflections is a major challenge for protein crystal 
structure solution and is usually achieved either via experimental phasing (most commonly using 
the anomalous scattering of X-rays by certain atoms) or, as in this study, by molecular 
replacement. This involves deriving initial estimates of phases from existing, similar protein 
structures aligned within the unit cell of the unknown structure (Evans and McCoy, 2008). These 
calculations, and the subsequent refinement of the model parameters and resulting phases, are 
performed computationally using extensive program suites developed within the crystallography 
community. 
  
The main aim of this investigation was to establish an understanding of the structure of the T. 
congolense lysyl-tRNA synthetase enzyme, including its complexes with its usual ligands and with 
potential inhibitors. This was to be achieved using protein X-ray crystallography, and therefore 
initially required the preparation and purification of highly pure recombinant forms of the enzyme 
suitable for crystal formation. Although the project initially focused solely on ‘LysRS1’, the cytosolic 
form of the lysyl tRNA synthetase, there was also scope to extend these studies to other 


















Materials & Methods  
  
Expression and Purification 
 
The T. congolense lysyl-tRNA synthetase I (LysRS1) gene had already been cloned into the hexa 
His-tagged vector pOPINE (Addgene plasmid #26043) during a previous study (McCready-Fallon, 









The vector was transformed into competent cells (Rosetta 2 pLacI – Novagen) as per the 
manufacturer’s instructions. Transformants, after being supplemented with 34 mg/mL 
chloramphenicol, 50 mg/mL carbenicillin and 1% w/v glucose, were then used to produce an 
overnight culture that was incubated overnight at 30°C whilst shaking at 180 rpm (Innova 44 
Incubator shaker series). This was then diluted by a factor of 100 and used to produce 1 L of liquid 
culture each, supplemented with the same additives as the overnight culture. Liquid cultures were 
grown in a 37°C incubator whilst shaking at 200 rpm. When they surpassed an OD600 reading of 
0.55 (measured using a DeNovix DS-11 spectrophotometer), they were transferred to a 20°C 
incubator for a final thirty minutes and then had 1 mM IPTG added to each culture to induce 
expression. At this point they were incubated overnight at the same temperature whilst shaking at 
180 rpm. The cultures were then spun down in a centrifuge at 5000 g for 45 minutes (Sorvall 
Evolution RC), after which the supernatant was discarded, and the cell pellets transferred to a new 
container (in most cases a Falcon tube).  
 
Pellets were resuspended in a volume of cobalt load buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 
5% w/v glycerol, 45 mM Imidazole) equal to 1/100th of the original volume of liquid culture, with 1 
protease inhibitor tablet added per 10 mL of mixture. The mixture was processed using a cell 
homogeniser to ensure a uniform consistency and then passed through a cell press (Constant 
Systems Cell Disruptor T5) at 25 kpsi to lyse the constituent cells. The resulting lysate was 
centrifuged at 18000 rpm for 45 mins (Sorvall RC6) and the supernatant was retained, whilst the 
pellet (cell debris) was discarded.  
 
Using a peristaltic pump (Cole-Parmer minipump variable flow), the supernatant was then loaded 
Figure 5: LysRS1 protein sequence. 
The pOPINE hexa His-tag is highlighted in red. 
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onto a 5 mL cobalt FPLC column (Generon) and washed through using cobalt load buffer. The 
column was set up on an ÄKTA afterwards and the protein was subsequently eluted using cobalt 
elution buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 5% w/v glycerol, 500 mM imidazole) on a 
linear gradient increasing from 0-60% over 30 mins. Promising fractions were identified using the 
UV trace on the ÄKTA and samples from each were taken and stored for later analysis with SDS-
PAGE. The promising fractions were then pooled together and concentrated using a 30,000 
MWCO concentrator tube (Generon Vivaspin 20) in a centrifuge (Sorvall ST40R) to a volume less 
than 5 mL. Using an ÄKTA, the concentrated sample was loaded onto a SEC column (Generon 6-
600 kDa HR resin) and washed through using GF buffer (25 mM HEPES pH 7.5, 500 mM NaCl, 
5% w/v glycerol). Just as before, the UV trace on the ÄKTA was used to monitor protein elution 
and samples from each promising fraction were taken and stored for later SDS-PAGE analysis. 
The His-tagged protein was predicted as ~61.2 kDa by the ExPASy ProtParam webtool (Gasteiger 
et al., 2005). The promising fractions were then, again, pooled and concentrated down to a 
suitable volume. Protein concentration was measured using the Protein280 application on a 
nanospectrophotometer device (DeNovix DS-11 spectrophotometer).  
 
When the cobalt FPLC column degraded in quality due to frequent usage, it was recharged 
through the following steps. First it was stripped by washing through with 5-10 column volumes of 
stripping buffer, washed with at least 5-10 column volumes of cobalt load buffer and then with 5-10 
column volumes of distilled water. This was all conducted using the peristaltic pump. To recharge 
the now-washed column, 2.5 mL of 0.1 M cobalt chloride was loaded onto the column. Then it was 
washed through with 5 column volumes of distilled water and 5 column volumes of cobalt load 
buffer. Finally, it was stored in 20% ethanol.  
  
Crystallisation  
The purified protein, at a known concentration, could then be used in crystallisation trials. In the 
meantime, it was stored at 4°C. If additives (such as L-lysine, ATP, MgCl2 or an inhibitor) were to 
be added, the solution would be made up with final concentrations in mind and then kept on ice for 
around fifteen minutes whilst the crystallisation apparatus was set up. All crystallisation attempts 
used the vapour diffusion method.  
 
Most crystallisation experiments took place in 2-drop 96-well MRC crystallisation plates, from 
Molecular Dimensions, using purchased matrix screens (JCSG-plus and PACT Premier). From 
successful results a custom matrix screen was devised and, additionally, 24-well plates were used 
early in the project to try and optimise crystallisation conditions in a similar manner.   
 
To conduct the experiments, several protocols were used on a Phoenix nanolitre pipetting robot 
(Art Robbins) to automate the dispensing of 50 μL of screen solution to plate reservoirs, 0.5 μL of 
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screen solution to the plate sitting drops, and ultimately 0.5 μL of sample solution to the sitting drop 
as well (thus a total drop size of 1 μL). Sealed plates were incubated at both 4°C and 20°C in a 
crystal hotel and examined regularly using Formulatrix imaging software under both visible and 
cross-polarised light.   
 
Crystallisation was attempted with a wide range of conditions – with both JCSG-plus and PACT 
premier screens, at both 4°C and 20°C, with different concentrations of protein (5-20 mg/mL) and 
with different combinations of additives at different concentrations (e.g. 100 mM L-lysine, 10 mM 
ATP, 10 mM MgCl2), and also without any additives. 
 
When promising crystals were produced, they were transferred at first to 1 µl drops of 
cryoprotectant solution using nylon loops. Later, it was found that cryoprotection was unnecessary 
and so they were – from then on – transferred directly into a storage puck within liquid nitrogen. 
The puck was then loaded into a dewar of liquid nitrogen, after which it was taken to Diamond 
Light Source for diffraction.  
 
Diffraction data collection and processing  
Diffraction data were collected on the Diamond light Source I04-1 beamline after crystals were 
loaded directly from the dewar into the cryostream via robotic arm. Initially, three test images of 
each crystal were taken (45° apart) to determine the potential quality of diffraction.  For those 
deemed promising, a full 1800 images were collected with an oscillation of 0.2°, 0.1 second 
exposure time and at a wavelength of 0.9159 Å. The detector was set to allow collection of data 
with a maximum resolution of 2.50 Å. 
 
iMosfilm (Battye et al., 2011) was usually used to process raw diffraction data. This program 
automatically identifies diffraction peaks, then indexes and integrates the data to produce a file 
containing reflection intensities and indices (mtz format) that could then be scaled and merged 
using Aimless. Aimless, and other programs mentioned below unless stated otherwise, are part of 
the CCP4 suite (Winn et al., 2011). In some cases, mtz files were taken directly from the auto-
processing functions (Autoproc & Xia2) that are automatically performed on the Diamond ISPyB 
website. This was done if the auto-processed data already looked usable – determined by the 
statistics provided on ISPyB such as whether the correct space group was selected, the 
completeness was good, and the resolution was useful. 
 
The Matthews cell analysis program was first performed to estimate the number of molecules in 
the asymmetric unit. PHASER, a molecular-replacement program that uses maximum-likelihood 
methods, was used to produce initial estimates of the phases by placing a search model within the 
asymmetric unit through both rotational and translational searches after first correcting for 
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anisotropy. An existing T. congolense LysRS1 structure (McCready-Fallon, 2018) served as the 
model for this search after all waters and ligands had been removed. The rotational and 
translational search results were filtered based on atomic clashes (packing analysis) and then 
simple rigid-body refinement was performed on the placed molecules. PHASER then calculates 
the theoretical phases (calc) of the model placed in the crystal unit cell and an initial electron 
density map is then generated through using these phase estimates in conjunction with the 
amplitudes observed in the actual experiment with the unknown crystal (Evans & McCoy, 2008). 
 
The resulting model then underwent a series of refinement cycles. Each involved adjusting the 
arrangement of atoms within the model molecule against the electron density map using the 
program Coot, and then optimising the fit using the program Refmac. As the model is adjusted the 
phase estimates derived from the model improve (i.e. better fit the crystal structure), leading to 
improved electron density maps (2Fobs-Fcalc) which, in turn, are used to further adjust the model. 
This iterative process was used to improve the accuracy of the model structure and was monitored 
by assessing the fit between model and map via Rcalc and Rfree values. The online web-tool 
Molprobity (Chen et al., 2010) was used to check that the stereochemistry parameters of the 
model, e.g. Ramachandran values and rotamer orientations, were consistent with the combined 
observations found in well-refined prior protein crystal structures. Amendments were made with the 
Molprobity results in mind, particularly when outliers were detected, though in some areas the 
electron density contradicted the Molprobity evaluations; in these instances, the electron density 
took priority. Existing structures in the PDB were sometimes used as a guide yet, just as with the 
Molprobity results, priority was always given to the experimentally derived electron density data. 
For example, with the attempt at solving an ATP-bound structure, a human lysyl-tRNA synthetase 
with ATP bound (3BJU – Guo et al., 2008) was used as a comparative reference for active site 
location and ligand orientation. The ligands were added only after the actual protein chain was 
deemed satisfactory, to avoid biasing the data.  
 
In addition to the tools provided by CCP4, the Phenix suite (Adams, 2010) was sometimes used as 
well. For example, when a structure first reached the point where Refmac5 made only negligible 
improvements, ‘AutoBuild’ was sometimes used to re-start the refinement. This software combines 
the density modification and chain tracing functions from the RESOLVE program with the 
automated refinement program phenix.refine to generate a model. It runs several parallel 
processes that each prioritise a different quality-indicator, and so progress in slightly different 
ways, and then amalgamates the results of each into a final model. Following any AutoBuild run, 
refinement would then continue as before using Refmac5 with consideration given to similar 
structures and Molprobity evaluations. When the structures approached a level that could be 
considered satisfactory, and Refmac5 again began to return only negligible improvements, 
phenix.refine was used in the final few iterations. Finally, the online wwPDB validation service was 
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used to provide an overview of final structure quality. 
 
For some comparisons made between the structures produced in this investigation and those of 
LysRS enzymes from other species reported previously, BLASTp (Altschul, 1990) was used to 
assess the similarity between sequences. AreaIMol (Lee and Richards, 1971), a program within 
the CCP4 suite, was used to calculate the solvent accessible surface area in different structures – 
as well as how much of it is buried during the binding of certain ligands. The structures were 
visualised in 3D using PyMOL (DeLano, 2002), which also predicted hydrogen bonding and 
allowed for structure alignments. The program LigPlot+ (Laskowski and Swindells, 2011) was used 
to predict hydrophobic and VDW contacts between ligand and binding site, and to produce 
supporting figures visualising these contacts alongside hydrogen bonds shown more clearly. 
 
Inhibitors  
To select potential inhibitors for use in this study, the NCI/DTP database was searched for 
molecules with over 80% similarity to the lysyl-AMP intermediate. Cladosporin was not included in 
this study due to sourcing difficulties; it is too expensive to buy from a commercial source and 
cannot be easily synthesised. The considered inhibitors are shown below in Table 1. 
Of the acquired inhibitors (structures shown in Figure 6), cordycepin and clofarabine were trialled 
in co-crystallisation with LysRS1. This was accomplished in the same way as the ATP trials, only 
that ATP was substituted with the inhibitor in question. Although the magnesium ions are thought 
to assist in phosphate positioning, and these nucleoside analogues have no phosphates, 
magnesium was still included in case it had other effects on the shape of the active site that could 







Table 1: Seven potential inhibitors of LysRS1 from the NCI database with over 80% 
similarity to the lysyl-AMP intermediate.  
Those acquired are highlighted in green. 
 
Figure 6: Acquired inhibitors.Table 1: Seven potential inhibitors of LysRS1 from the 
NCI database with over 80% similarity to the lysyl-AMP intermediate.  









































Figure 6: Acquired inhibitors. 
This shows the structure of the three inhibitors acquired for this study: cordycepin (left), cladribine 




Results & Discussion 
 
Expression and Purification 
The protein was successfully produced, extracted and purified through the several processes.  
 
A representative cobalt FPLC trace from the ÄKTA is seen in Figure 7. The well-defined peak 
shows that this stage is working as intended; the unwanted contents have been washed off and 
then, as the gradient of elution buffer is increased, the protein is gradually eluted to produce 
promising fractions (A7-B7 in this instance). 
  
Figure 8 below shows one of the SDS-PAGE gels run – it displays the effects of the cobalt FPLC 
column step and provides evidence that the correct protein is being expressed. The thick banding 
in the promising fraction lanes is situated around 70 kDa despite the molecular weight of the His-
tagged LysRS1 protein being predicted as ~61.2 kDa. A similar discrepancy occurred in a previous 
study (McCready-Fallon, 2018) where peptide mass fingerprinting was then used to verify that the 
bands do contain LysRS1. Many proteins run at different molecular weights than predicted values 
on a gel, often due to them running as elongated rather than globular structures. This discrepancy 
has therefore been ignored. The protein is known to dimerise in solution via a dimeric interface, 
rather than any disulphide bonding, hence why it is seen as monomeric on the denaturing SDS-
PAGE gel. 
Figure 7: Cobalt FPLC column trace graph. 
This is an example trace graph tracking the progress of a cobalt FPLC column run. The 
blue line measures UV absorbance, whereas the dark green line indicates the elution 
buffer gradient. Fractions are labelled at the bottom in red. 
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Figure 8: Example Post-
Cobalt SDS-PAGE gel.  
From the left, the first lane 
contains the marker. The 
second shows the contents of 
the sample before the column. 
The remaining lanes show the 
























Figure 9: SEC column trace graph.  
An example trace graph tracking the progress of a SEC column run. The blue line 










Figure 9 displays another representative trace from the SEC; another clear peak, with the rest of 
the UV trace remaining comparatively flat, indicates that the protein is being washed through the 







Figure 10: Example 
Post-SEC SDS-PAGE 
gel. 
From the left, the first lane 
contains the marker. The 
second shows the 
contents of the sample 
before SEC. The 
remaining lanes show the 




























Figure 10 shows another of the SDS-PAGE gels, this one run after a SEC column, showing that 
the protein has been further purified by this step and confirming that the protein has not been lost 
during the process. 
 
Crystallisation 
LysRS1 could be crystallised from a variety of different well conditions, though there was no 
success when using a custom screen based on the most frequently successful wells of the 
commercial 96-well PACT premier screen. Early attempts at optimising crystallisation conditions in 
24-well plates were unsuccessful, potentially due to difficulties in storing plates at 4°C; all crystals 
obtained in this investigation have been grown at 4°C, with no success at 20°C. 
 
Three structures have been produced in this investigation, each containing different ligands bound 
to the LysRS1 structure. Structure ‘LAM_H2’ has the lysyl-AMP intermediate bound to one chain 
and the other only containing lysine. Structure ‘LCM_F3’ has the nucleoside analogue cordycepin 
bound in both chains alongside lysine. Structure ‘LAM_G4’ contains AMP and lysine in the active 
sites of both chains. Of these, the most important are the former two – LAM_H2 is thought to be a 
good representation of the enzyme structure during activity and LCM_F3 provides an opportunity 
to evaluate how a nucleoside analogue could function as an inhibitor to this system. That said, 




Figure 11: LysRS1 + L-Lysine + ATP + MgCl2 (LAM_G4) crystals.  
Sample solution consisted of 20 mg/mL protein, 100 mM L-lysine, 10 mM ATP and 10 mM 
MgCl2. 0.5 μl of this was added to 0.5 μl well (G4, PACT Premier) solution – 20% PEG 3350, 
0.2 M KSCN and 0.1 M Bis-Tris Prop pH 7.5 buffer. Incubated at 4°C and inspected regularly.  
Figure 12: LysRS1 + L-Lysine + ATP + MgCl2 (LAM_H2) crystals.  
Sample solution consisted of 20 mg/mL protein, 100 mM L-lysine, 10 mM ATP and 10 mM 
MgCl2. 0.5 μl of this was added to 0.5 μl well (H2, PACT Premier) solution – 20% PEG 3350, 
0.2 M NaBr and 0.1 M Bis-Tris Prop pH 8.5 buffer. Incubated at 4°C and inspected regularly. 
The crystals that diffracted to give LAM_G4, the highest resolution LAM (L-lysine + ATP + MgCl2) 
structure, were produced in a 96-well plate using a commercial PACT premier screen, within the 
well ‘G4’ that contained 20% w/v PEG 3350, 0.2 M KSCN and 0.1 M Bis-Tris Prop pH 7.5 buffer. 
The protein solution itself consisted of 20 mg/mL protein, 100 mM L-lysine, 10 mM ATP and 10 
mM MgCl2 – high additive concentrations were used to maximise the chance of binding. They 




The LAM_H2 crystals were also produced in a 96-well plate using a commercial PACT premier 
screen, within the well ‘H2’ that contained 20% PEG 3350, 0.2 M NaBr and 0.1 M Bis-Tris Prop pH 
8.5 buffer. This protein solution was the same as in LAM_G4 – 20 mg/mL protein, 100 mM L-
lysine, 10 mM ATP and 10 mM MgCl2. They are shown in Figure 12. 
 
Finally, LCM_F3 came from crystals produced in well ‘F3’ in a 96-well plate using a commercial 
PACT premier screen. This well contained 20% PEG 3350, 0.2 M NaI and 0.1 M Bis-Tris Prop pH 
6.5 buffer. The protein solution consisted of 20 mg/mL protein,100 mM L-lysine, 10 mM cordycepin 






























Figure 13: LysRS1 + L-Lysine + Cordycepin + MgCl2 (LCM_F3) crystals.  
Sample solution consisted of 20 mg/mL protein, 100 mM L-lysine, 10 mM Cordycepin and 10 
mM MgCl2. 0.5 μl of this was added to 0.5 μl well (F3, PACT Premier) solution – 20% PEG 





Figure 14: LysRS1 LAM_G4 crystal. 
The crystal is pictured within a nylon loop at Diamond Light Source. It 
was found to belong to the space group P6522 and diffracted to 1.9Å 
 




















With a previous batch of crystals, it was found that cryoprotection was unnecessary. Therefore, the 
crystals that produced the best structures had been taken and had diffraction data collected at 
Diamond Light Source without cryopreservation. Figure 14 shows the LAM_G4 crystal within the 






















The initial data collection statistics are seen above in tables 2, 3 and 4. The Matthews cell analysis 
program in CCP4 was used to estimate the number of molecules in the asymmetric unit. The 
results from the use of this program are summarised in tables 5, 6 and 7. They each show that 

















Tables 8, 9 and 10 show summaries from the PHASER molecular replacement results for each 
structure. These tables detail the best potential solutions for the translational and rotational 
searches undertaken by the program. LLG is a measure of quality that refers to how much better 
the data can be predicted using the found model compared to using a random distribution of the 
same atoms. The Z-score indicates how many standard deviations above the mean that potential 
solution is. The best solution was clear in each instance as shown by the LLG and Z-score of said 




Table 7: Matthews program result for LCM_F3. 
The table indicates the different potential solutions and then the probability for each solution, 
calculated using the high resolution limit (P(2.44) in this case) and the total probability 
across all resolution ranges P(tot). 
 
Table 5: Matthews program result for LAM_G4. 
The table indicates the different potential solutions and then the probability for each solution, 
calculated using the high resolution limit (P(1.94) in this case) and the total probability 
across all resolution ranges P(tot). 
 
Table 6: Matthews program result for LAM_H2. 
The table indicates the different potential solutions and then the probability for each solution, 
calculated using the high resolution limit (P(2.22) in this case) and the total probability 













Table 9: PHASER MR rotational (left) and translational (right) searches for LAM_H2. 
The tables detail the best potential solutions ranked by log likelihood gain (LLG). The top 20 
possible solutions of the translational search are shown. 
 
Table 8: PHASER MR rotational (left) and translational (right) searches for LAM_G4. 
The tables detail the top potential solutions ranked by log likelihood gain (LLG).  
and then the scores for each.  
 
 
Table 9: PHASER MR rotational (left) and translational (right) searches for 
LAM_H2.Table 8: PHASER MR rotational (left) and translational (right) searches for 
LAM_G4. 
The tables detail the top potential solutions ranked by log likelihood gain (LLG).  




Table 10: PHASER MR rotational (left) and translational (right) searches for LCM_F3. 
The tables detail the top potential solutions ranked by log likelihood gain (LLG). In each 
case the top 20 possible solutions are shown. 
 
















In all structures the final translational function Z-score (LAM_G4, 114.3; LAM_H2, 107.1; LCM_F3, 
90.0) exceeded 8 indicating, according to PHASER guidelines, there was a very high probability 
this was a correct solution. 
 
All three structures have been subject to numerous refinement cycles to improve the models and 
to try and determine whether there are bound ligands and, if so, what they are. The statistics of the 













































As seen in Table 13, the structure LCM_F3 has an average water B-factor lower than that of the 
protein chain itself. This is likely the result of a more conservative approach to modelling waters in 
which only tightly bound waters have been included.  
 
Overall structure 
The overall fold of the structures solved in this investigation is consistent with previous reports of 
class II aminoacyl-tRNA synthetases (Ling Joy Pang, 2014) and as previously described for this 
same enzyme (McCready-Fallon, 2018). In brief, each LysRS1 molecule consists of two main 
components: the anticodon-binding domain and the aminoacylation domain. The anticodon binding 
domain is constructed around a beta-barrel at the N-terminus whereas the aminoacylation domain 




Figure 15: Overall structural view of LAM_H2 monomer. 
The N-terminal anticodon binding domain is coloured blue and the C-terminal 
aminoacylation domain is coloured magenta. Within the aminoacylation domain, motifs 
1, 2 and 3 are coloured red, orange and brown, respectively. This image was produced 
using chain B of LAM_H2. 
 
is comprised of seven antiparallel beta-strands flanked by a series of alpha helices of varying 
length, an arrangement seen very rarely in non-aaRS proteins.  
Each structure contains two molecules of LysRS1 forming a back-to-back dimer. Motif 1 is found at 
the dimeric interface between each monomer, whereas motifs 2 and 3 are part of the 
aminoacylation site. These structural features are highlighted below, shown as a monomer in 















Figure 16: Overall structural view of LAM_H2 dimer. 
The N-terminal anticodon binding domain is coloured blue and the C-terminal 
aminoacylation domain is coloured magenta. Within the aminoacylation domain, motifs 




These figures were produced using the LAM_H2 structure but there are no major differences in the 
structural elements of the three structures solved in this investigation. To show this, C-alpha traces 
have been produced for each structure and then overlaid against the existing Tcon LysRS1 
















In order to highlight any major differences between these structures and the existing one, another 
trace has been prepared that shows the same comparison as above but this time coloured by 
RMSD. As expected, Figure 18 shows that these structures are very similar except for two loops 
that will be examined later in more detail. In addition to those loops, there are some areas where 
the RMSD values are higher. These are thought to be insignificant due to being located on external 
parts of the protein where the chain is more flexible and (as a consequence of this) the electron 
density maps are less clear. 
Figure 17: Combined C-alpha trace overlay. 
This figure shows the C-alpha traces of four structures overlaid: the three structures 
from this investigation (LAM_H2; green, LAM_G4; blue and LCM_F3; red) and the 




Figure 18: Combined C-alpha trace overlay coloured by RMSD. 
This figure shows the C-alpha traces of four structures overlaid: the three structures from 
this investigation (LAM_H2, LAM_G4 and LCM_F3) and the existing Tcon LysRS 
structure fully-complexed with lysine (grey). The RMSD values (Å) for these alignments 
are 0.42, 0.28 and 0.39, respectively. A PyMOL script was used to align each of the new 
structures to the existing one and then colour them by local RMSD. A rainbow spectrum 
of colours indicates relative RMSD, starting at a dark blue for minimum RMSD ranging 
down to red for maximum RMSD. Red arrows indicate the loops that deviate from their 
conformation in the existing structure. 
 
 
Now that it has been shown that there are no major deviations in the overall structural arrangement 
when compared to the existing Tcon LysRS model, the structures were compared to one another 











Figure 19: C-alpha trace overlay coloured by RMSD (LAM_H2 v LAM_G4). 
This figure shows the C-alpha traces of LAM_H2 and LAM_G4. The overall RMSD for this 
alignment is 0.34 Å. A PyMOL script was used to align the two structures and then colour them 
by local RMSD. A rainbow spectrum of colours indicates relative RMSD, starting at a dark blue 
for minimum RMSD ranging down to red for maximum RMSD.  
Figure 20: C-alpha trace overlay coloured by RMSD (LAM_H2 v LCM_F3). 
This figure shows the C-alpha traces of LAM_H2 and LCM_F3. The overall RMSD for this 
alignment is 0.39 Å. A PyMOL script was used to align the two structures and then colour 
them by local RMSD. A rainbow spectrum of colours indicates relative RMSD, starting at a 






As with the previous overlays, there appear to be no significant deviations between these 
structures – most discrepancies seen are negligible, on the external surface of the protein and/or 
contained to short (~1-3 residue) sections. There is one exception, aside from the loops already 
mentioned, which is in the comparison between LCM_F3 and LAM_G4 (Figure 21). Two adjacent 
areas are distinctly displaced from one another in the alignment, as highlighted in Figure 22. Due 
to the proximity of the first area (residues ~310-315) to the ATP-binding site, this discrepancy could 









Figure 21: C-alpha trace overlay coloured by RMSD (LAM_G4 v LCM_F3). 
This figure shows the C-alpha traces of LAM_G4 and LCM_F3. The overall RMSD for 
this alignment is 0.21 Å. A PyMOL script was used to align the two structures and then 
colour them by local RMSD. A rainbow spectrum of colours indicates relative RMSD, 




Figure 23: Combined C-alpha trace overlay (Chain A). 
This figure shows the C-alpha traces of four structures overlaid: the three structures from 
this investigation (LAM_H2; green, LAM_G4; blue and LCM_F3; red) and the existing 
Tcon LysRS structure fully-complexed with lysine (black). This image is zoomed in on the 
area within chain A where a discrepancy has been identified (residues ~310-315). 
 
Figure 22: Area of higher deviation (LAM_G4 v LCM_F3). 
This shows a zoomed-in view of the area identified in Figure 21, with the bound ligand 
from each structure (AMP from LAM_G4, light blue; Cordycepin from LCM_F3, red) 
















As shown in figures 23 and 24, this discrepancy is seen only in chain A: LAM_G4 and the existing 
structure have these sections of residues (~310-315 and ~270-275) further away from the ATP-
binding site than in LCM_F3 and LAM_H2. If this was observed in both chains, it could be 
suggested that this is part of a conformational change to promote non-optimal binding of 
cordycepin, a non-native ligand, and the lysyl-AMP intermediate due to a lack of tRNA with which 
to continue the reaction. But it is seen only in chain A, despite all of the structures except LAM_H2 















Figure 24: Combined C-alpha trace overlay (Chain B). 
This figure shows the C-alpha traces of four structures overlaid: the three structures from 
this investigation (LAM_H2; green, LAM_G4; blue and LCM_F3; red) and the existing 
Tcon LysRS structure fully-complexed with lysine (black). This image is zoomed in on the 
area within chain B where a discrepancy is seen in the equivalent area in chain A 
(residues ~310-315). 
 
Every chain was aligned together, as seen in Figure 25, and this region was then examined more 
closely. Out of both chains in every structure, only chain A of LAM_G4 and chain A of the lysine-
only structure has this region further away from the ATP-binding site. As mentioned before, both 
structures contain the same ligands bound in both chains. This suggests that the alternative 
conformation observed in chain A of the lysine-only structure reflects the flexibility in this region 
when the ATP-binding site is empty. In LAM_G4, the alternative conformation in chain A therefore 
















Table 14: Compiled alignment RMSD values. 
This figure shows RMSD values of the alignments made in this section. ‘Existing’ refers 
to the existing structure containing Tcon LysRS fully complexed with lysine. 
 
Figure 25: Combined C-alpha trace overlay (All chains). 
This figure shows the C-alpha traces of all chains in four structures overlaid. The 
structures solved in this investigation (LCM_F3 chain A, blue; LCM_F3 chain B, yellow; 
LAM_G4 chain A, magneta; LAM_G4 chain B, teal; LAM_H2 chain A, wheat; LAM_H2 
chain B, grey) and the existing Tcon LysRS structure fully-complexed with lysine (Chain A, 
red; chain B, green). This image is zoomed in on the area of the discrepancy (residues 
~310-315). 
; LAM_H2 chain A, wheat; LAM_H2 chain B, grey) and the existing Tcon LysRS structure 
fully-complexed with lysine (Chain A, red; chain B, green). This image is zoomed in on the 



























As seen in Table 14, the most closely aligned structures are LCM_F3 (Cordycepin) and LAM_G4 








Figure 26: Overview of LAM_H2. 
This image shows an overview of the LAM_H2 structure, produced in 
PyMOL. Chain A is in red, chain B is in blue and the ligands are magenta. 
The active sites are indicated by yellow rings. 
 
LAM_H2 
In the LAM_H2 crystal structure the two molecules in the asymmetric unit are very similar but not 
identical: they differ primarily in two loop regions and their respective active sites as described 
below. A cartoon representation of the entire structure is seen below in Figure 26 with each chain 
coloured differently, indicating the secondary structural composition of the protein as well as the 
positions of the active site relative to the rest of the macromolecule. The overall fold of the 



















Figure 27 displays another C-alpha trace comparison, this time between the two monomers in 














A significant difference between the two copies of LysRS1 in the LAM_H2 crystal structure is the 
active site content. In chain A the active site contains electron density consistent with a bound 
lysyl-AMP intermediate (Figure 28), whereas in chain B lysine alone appears to be bound (Figure 
29). This result was unexpected as the crystallisation content contained both lysine and ATP 










































Figure 28: LAM_H2, active site of chain A. 
This image shows the active site of chain A in the LAM_H2 structure. The lysyl-
AMP intermediate is highlighted in purple, whereas binding residues are shown 
green and labelled in black. Hydrogen bonds are shown as yellow dotted lines.  
Figure 27: C-alpha trace overlay coloured by RMSD (LAM_H2_A v LAM_H2_B). 
This figure shows the C-alpha traces of chain A and chain B of LAM_H2. The RMSD for 
this alignment is 0.53 Å. A PyMOL script was used to align the two structures and then 
colour them by local RMSD. A rainbow spectrum of colours indicates relative RMSD, 
starting at a dark blue for minimum RMSD ranging down to red for maximum RMSD. 
Grey indicates areas that were excluded from the alignment. The lysyl-AMP intermediate 




The active site electron density in molecule A (Figure 28) was very clear and is consistent with the 
presence of a lysyl-AMP intermediate interacting with mainly side chains of a number of residues 
in the active site of chain A. Tyr324, Tyr483, Glu485 and Glu284 all form hydrogen bonds with the 
epsilon amino group from the ‘lysyl’ moiety of the intermediate. Glu284 forms a second hydrogen 
bond, together with Glu322, with the alpha amino group of that area. Arg306 hydrogen bonds with 
both the carboxyl group and the phosphate itself. On the ribose, Glu478 and Ile479 (main chain 
carbonyl) again can be seen to both hydrogen bond with both the 2’- and 3’-hydroxyl groups. The 
Asn315 main chain amide group hydrogen bonds with the adenine ring and the adenine amino 
group. 
 
As might be expected, the binding interactions for the lysyl-AMP intermediate essentially consist of 
















The active site of chain B (Figure 29) exhibits electron density consistent only with a bound lysine 
and the other half of the binding pocket appearing to be occupied by waters as seen in the 
previously reported ‘lysine only’ LysRS structures (McCready-Fallon, 2018). This conclusion was 
reached because the density data in that pocket is disconnected, failed to improve when any of the 
potential ligands (ATP, AMP, intermediate) were added in, and nor does it appear to be in the 
expected orientation for any of those potential ligands.  
 
The lysine substrate is bound via a cluster of hydrogen bonds between its alpha amino group and 
the nearby Glu284, Gly260 (main chain carbonyl) and Glu322 residues. This Gly260 is part of a 
loop that seems to appear in either of two conformations and so this hydrogen bond, among the 














Figure 29: LAM_H2, active site of chain B. 
This image shows the active site of chain B in the LAM_H2 structure. The lysine 
ligand is highlighted in purple, whereas binding residues are shown green and 
labelled in black. Hydrogen bonds are shown as yellow dotted lines. Phe318 is 
shown as a reference point. Density interpreted as bound water molecules is shown 




Figure 30: LAM_H2 chain A lysine-binding site in LigPlot. 
This is a schematic of the chain A lysine-binding site of LAM_H2, prepared using LigPlot. 
It shows the hydrogen bonds (green dotted lines) more clearly and provides information 
on residues/atoms involved in either hydrophobic or VDW contacts (red crescents) with 
the bound ligand. 
 
conformation, is only seen in chain B of LAM_H2. It is possible that this loop works to anchor the 
lysine in place prior to the binding of the ATP, at which point the reaction occurs and the loop 
moves away from the active site into its other conformation. One hypothesis is that this could 
potentially promote the binding of tRNA following ATP hydrolysis. Finally, the bound lysine 
carboxyl group also forms a hydrogen bond with the side chain amide nitrogen of Asn481.  
 
In addition to hydrogen bonding, the site has a number of residues that are involved in hydrophobic 
or Van Der Waals (VDW) contacts with the bound ligand(s). These residues contribute to shape 
complementarity of the enzymatic site to the substrates and, crucially, help prevent incorrect 

























Figure 31: LAM_H2 chain A ATP-binding site in LigPlot. 
This is a schematic of the chain A ATP-binding site of LAM_H2, prepared using LigPlot. It 
shows the hydrogen bonds (green dotted lines) more clearly and provides information on 



























































Table 15 has been prepared to summarise the residues in each of these sites involved in 












Figure 32: LAM_H2 chain B lysine-binding site in LigPlot. 
This is a schematic of the chain B lysine-binding site of LAM_H2, prepared using LigPlot. 
It shows the hydrogen bonds (green dotted lines) more clearly and provides information 
on residues/atoms involved in either hydrophobic or VDW contacts (red crescents) with 
the bound ligand. 
 
Table 15: Summary of hydrophobic or VDW contacts in LAM_H2 catalytic sites. 
This table lists the residues that are involved in hydrophobic or VDW contacts with the 




Structural changes in and around the active site 
Comparative analysis of the LysRS1 active sites has highlighted two loop regions of significant 
interest in these structures. The first of these, consisting of residues 258-265 (AGGAAARP), will be 
termed ‘Loop-Alpha’, and the second which is an external surface loop roughly consisting of 
residues 500-514 (LRDREKGDDEAMSID), will be referred to as ‘Loop-Beta’.  
 
Loop-Alpha is inherently interesting because it contains a residue (Gly260) that is ligand-binding in 
LAM_H2 chain B and the previous structures of this enzyme complexed with lysine, yet far apart 
from the active site in the other structures solved in this investigation. This is consistent with a 
conformational change during enzyme activity. Loop-Beta is often poorly defined in the existing 
crystal structures of this enzyme, with no corresponding density in most chains and only patchy 
density where there is any. While this is not unusual for an external loop that is likely very flexible, 
Loop-Beta is important because its location is adjacent to the position of Loop-Alpha; that is, their 
movements are potentially linked as part of the same concerted conformational change.  
 
In the structures solved during this investigation there are two apparent, distinct conformations for 
Loop-Alpha which will simply be referred to as ‘1’ and ‘2’. Conformation 1 places Gly260 close to 
the bound lysine, where it forms a main chain hydrogen bond to the alpha-amino group. This is 
shown below in Figure 33. When this conformation is observed, Loop-Beta does have 
representation in the density – whether patchy or clear, there is an indication of where Loop-Beta 



















Conformation 2 places Gly260 further from the active site and, when this conformation of Loop-
Alpha is observed, there is a complete absence of any density that could conceivably represent 
Loop-Beta. When Loop-Alpha is in conformation 1, Loop-Beta occupies the space that Loop-Alpha 
















Figure 33: LAM_H2, Loop-Alpha of chain B – “Conformation 1”. 
This image shows the position of Loop-Alpha, highlighted in red, with respect to the active site 
of chain B. A dotted line shows the distance in Å between Gly260 and the alpha-amino group 




Figure 34: LAM_H2, Loop-Alpha of chain A – “Conformation 2”. 
This image shows the position of Loop-Alpha, highlighted in red, with respect to the 
active site of chain A. A dotted line shows the distance in Å between Gly260 and 





















In LAM_H2, Loop-Alpha is in conformation 1 in chain B where only lysine is bound in the active 
site. This is in concurrence with the previously reported structures of Tcon LysRS1, where Loop-
Alpha is also seen in conformation 1 in chains where lysine alone is present.  
 
In contrast, in chain A where the intermediate is present Loop-Alpha can be seen clearly to be in 
conformation 2 despite slightly patchier density for it. The ‘semi-complexed’ Tcon LysRS1 
(McCready-Fallon, 2018), in the chain where there are no ligands bound in the active site, has 
Loop-Alpha in a position resembling this conformation 2. This may indicate that the binding of 
lysine induces a conformational change that promotes the binding of ATP. After ATP binds and 
undergoes hydrolysis to AMP and then condensation to lysyl-AMP, another conformational change 
takes place which reverts the loops back to their original positions. This could be to promote tRNA 
binding or simply to, in this case where there is no tRNA to facilitate the next stage of the reaction, 
instead facilitate the replacement of the intermediate by another ATP – to initiate the catalytic cycle 
once again. Although this analysis is conjecture at this stage, the role of these loops will be 







Table 16: Summary of alignment between 6CHD and F1MMK8. 
 
Comparison with 6CHD 
No structures of bovine LysRS exist in the PDB, and the sequence for this enzyme on Uniprot – 
F1MMK8 – is only partially validated. Even so, a BLASTp search was conducted using the 
F1MMK8 sequence and this returned a high similarity (Table 16) with mitochondrial human LysRS 
(Q15046-2) for which there are two structures (3BJU and 6CHD) in the PDB. 3BJU has already 
been mentioned earlier in this investigation as a tetrameric human LysRS enzyme with ATP and 
lysine bound to each chain, and 6CHD is a recently-uploaded structure to the PDB but for which 
there is no associated publication. In this structure human LysRS has an intermediate analogue 
(the phosphorus atom is instead a sulphur) bound in both active sites of the dimer. Due to its high 
sequence similarity to bovine LysRS and with no obvious alternative, 6CHD was used as a model 
in comparisons of LAM_H2 with a mammalian intermediate-containing LysRS structure. The aim 
was to identify any significant differences that could prove key to the development of a drug that 




























Figure 35: LAM_H2 (green & purple) v 6CHD (yellow & orange). 
This image shows the intermediate-occupied active site of LAM_H2 overlaid with 
the active site of 6CHD (Human LysRS). LAM_H2 is coloured with green carbons, 
and the intermediate is magenta, whereas 6CHD is coloured with yellow carbons 
and the intermediate analogue is orange. Hydrogen bonds match the colour of the 






























As can be seen in Figure 35, the intermediate analogue in 6CHD fits into the active site in a very 
similar manner to the actual intermediate observed in LAM_H2. Most residues of interest are the 
same but for two notable exceptions – Glu308 (LAM_H2) / Glu325 (6CHD) and Gly260 (LAM_H2) / 
Gly277 (6CHD). In LAM_H2, the glutamate at position 308 is twisted away from the active site and 
so can be surmised to not be involved in ligand binding. This is the case in every T. congolense 
LysRS structure in this investigation and the two previously reported which only contained lysine.  
 
The second major difference between these two active sites is the glycine, part of ‘Loop-Alpha’. As 
seen in Figure 35, Loop-Alpha is in conformation 1 in 6CHD. In LAM_H2, as mentioned earlier, it is 
in conformation 1 when lysine is alone in the active site and in conformation 2 when the 









Figure 36: LAM_H2 v 6CHD Loop-Alpha comparison. 
This image is a comparison between LAM_H2 and 6CHD that shows the two 
different conformations of Loop-Alpha. LAM_H2 chain A (intermediate-bound) is 
green, chain B (lysine-bound) is red, and 6CHD (intermediate analogue) is yellow. 























It is not immediately clear why Loop-Alpha is in different conformations in these structures. One 
possibility is simply that this is a major difference between the mammalian and trypanosome 
enzymes. It could also be that the enzyme is distinguishing between the (presumed) real lysyl-
AMP intermediate in LAM_H2, which would facilitate normal enzyme function, and the sulphur-
containing intermediate analogue used in 6CHD that inhibits the enzyme. 
 
Free AMP 
The LAM_H2 structure contains a ‘free’ AMP bound to each of the active sites, as illustrated in 
Figures 37 and 38. In both instances the AMP adenyl ring pi-stacks with Tyr349 and forms 
hydrogen bonds with Lys355, although the ribose 2’-oxygen from free AMP in chain A also forms a 















































Figure 38: LAM_H2, free AMP at chain B. 
The free AMP is shown in magenta, while the two residues of interest are in green 
and labelled in black. The image is at a slightly different angle than the previous 







Figure 37: LAM_H2, free AMP at chain A. 
The free AMP is shown in magenta, while the two residues of interest are in green 









Figure 39: Overview of LAM_G4. 
This image shows an overview of the LAM_G4 structure, produced in 
PyMOL. Chain A is in red, chain B is in blue and the ligands are magenta. 
The active sites are indicated by yellow rings. 
 
LAM_G4 
The LAM_G4 crystal structure contains homodimeric LysRS1 with each active site occupied by 
both lysine and AMP. Figure 39 shows a cartoon rendering of the entire structure, featuring the 





















In order to confirm the similarities and assess any major differences between the folding of the 














Figure 41:  Lysine bound to chain A and chain B in LAM_G4. 
This image shows the lysine ligands bound to the active site in chain A (left) and the 
active site in chain B (right), in LAM_G4. Residues of interest are coloured green 






































As seen in Figure 41, there is clear density for a lysine substrate in both active sites. In both cases 
the lysine is held by the same five residues within the active site, as also reported in a previous 
study (McCready-Fallon, 2018). Residues Glu284, Tyr324 and Glu485 hydrogen bond to the 
terminal amine group on the side chain of the lysine ligand. Glu284 also forms hydrogen bonds 
with the main chain alpha-amino group along with Glu322, and Asn481 hydrogen bonds the 
carbonyl oxygen. Information on the residues/atoms forming hydrophobic or VDW contacts with 
Figure 40: C-alpha trace overlay coloured by RMSD (LAM_G4_A v LAM_G4_B). 
This figure shows the C-alpha traces of chain A and chain B of LAM_G4. The overall 
RMSD of this alignment is 0.30 Å. A PyMOL script was used to align the two and then 
colour them by local RMSD. A rainbow spectrum of colours indicates relative RMSD, 
starting at a dark blue for minimum RMSD ranging down to red for maximum RMSD. 
Grey indicates areas that were excluded from the alignment. Bound AMP is visible to 




Figure 42: LAM_G4, chain A lysine-binding site. 
This is a schematic of the lysine-binding site of LAM_G4 chain A, prepared using 
LigPlot. It shows the hydrogen bonds (green dotted lines) more clearly and provides 
information on residues/atoms involved in hydrophobic or VDW contacts (red 
crescents) with the ligand. As the Tyr324 hydrogen bond reported by PyMOL is not 
predicted by LigPlot, it is likely weak or has geometry that is not ideal. 
 
Figure 43: LAM_G4, chain B lysine-binding site. 
This is a schematic of the lysine-binding site of LAM_G4 chain B, prepared using 
LigPlot. It shows the hydrogen bonds (green dotted lines) more clearly and provides 
information on residues/atoms involved in hydrophobic or VDW contacts (red 
crescents) with the ligand. 
 
the bound lysine ligands in these sites is provided below in figures 42 and 43, and later listed along 








































Unfortunately, despite the structure LAM_G4 fielding the highest resolution of the three structures, 
the other half of the active site has density that remains unclear mainly due to the absence of 
distinctive electron density for any potential phosphate groups. This made it difficult to determine 
whether it is AMP or ATP, or even the intermediate, which is bound in this site. 
 
The adenine nucleobase has well-defined density in both chains and is certainly present, pi-
stacking with the R-group of Phe318 as seen in 3BJU. In addition, the density supports the 
presence of the ribose and now indicates clearly its conformation. The phosphate region on the 
other hand was ambiguous – in both chains the density was insufficiently clear to define how many 
phosphate groups were present, and whether there is an ester linkage between the lysine ligand 
and this nucleotide. 
 
During the refinement process, multiple different molecules were inserted into the site to determine 












One other complication – or clue – was the presence of ‘free’ AMP molecules, one in each chain, 
pi-stacking with Tyr349. These are very clearly represented in the electron density and indicate 
that the enzyme is functioning – only ATP was added to the solution and so any AMP is most likely 
to have been formed as a result of enzyme activity.  
 
Figure 44: Investigation of potential nucleotide-based molecule. 
The left column shows the active site of chain A and the right column shows the active site of chain B. The 
first row shows the structure with L-lysine and adenosine placed in the binding site. The second row 
shows the structure with L-lysine and AMP in the site. The third row shows the structure with L-lysine and 




Figure 45: Free AMP in chain A. 
In chain A, the ‘free’ AMP ligand (magenta) forms two hydrogen bonds with 
Lys355 and pi-stacks with Tyr349. 
 
However, if the enzyme is functioning, it should only be capable of reaction step 1 because there is 
no tRNA present to facilitate step 2. Step 2 is where AMP is released and so, if the enzyme can 
perform step 1 in these conditions, there should only be ATP and/or lysyl-AMP in the structure – as 
reactant and product, respectively, of that first step. The intermediate is known to be unstable in 
solution which usually keeps it from dissociating from the enzyme before the second stage begins 
(Onesti, 2000). However, as the rate of reaction is presumably slow at these low temperatures and 
there is no tRNA to permit the next step of the reaction, one potential explanation is that the 
intermediate is being outcompeted by the high concentration of substrates. Upon being displaced 
from the active site, the intermediate breaks down, hence the free AMP molecules. 
 
In figures 45 and 46, the ribose oxygen of the free AMP in chain B can be seen to form a hydrogen 
bond with the main chain carbonyl of Tyr349, but otherwise those in both chain A and B form two 
hydrogen bonds with Lys355 and pi-stacking interactions with that Tyr349. Figures 47 and 48 
detail the residues that form hydrophobic or VDW contacts with the free AMP in each chain. These 
ligands are on the external surface of the protein and do not bind as strongly as those in the 
catalytic site.  
 
As seen earlier in the overall structure image in Figure 39, the catalytic site is relatively close by 
































































Figure 46: Free AMP in chain B. 
In chain B, the ‘free’ AMP ligand (magenta) is seen to form two hydrogen bonds 





Figure 47: LAM_G4, free AMP at chain A. 
This is a schematic of the free AMP in LAM_G4 chain A, prepared using LigPlot. It 
shows the hydrogen bonds (green dotted lines) more clearly and provides 
information on residues/atoms involved in hydrophobic or VDW contacts (red 




Figure 48: LAM_G4, free AMP at chain B. 
This is a schematic of the free AMP in LAM_G4 chain B, prepared using LigPlot. It 
shows the hydrogen bonds (green dotted lines) more clearly and provides 
information on residues/atoms involved in hydrophobic or VDW contacts (red 
























Ultimately, after many cycles of refinement the best fit to the electron density data has been 
determined as AMP. First, although the density around this ligand is patchy it is connected and 
resembles the shape of one of the three possible ligands, and the continuity of the density makes it 
very unlikely to be just water in the active site. Second, despite the phosphate lacking an obvious 
position, it is clear that there must be at least one phosphate group present as no part of the 
reaction involves or produces adenosine. In lysyl-tRNA synthetase structures that contain ATP, 
metal ions are often found stabilising the three phosphate groups; in a structure where the 
intermediate is present (1E1T; E. coli LysRS complexed with the intermediate) they are found near 
the two hydrolysed phosphate groups. In the active sites of this LAM_G4 structure there are no 
areas of density that could represent the magnesium ions present in the crystal solution, so it is 




Table 17: SASA differences in LAM_G4 
This was calculated by running AreaIMol on LAM_G4 to calculate solvent accessible 
surface area, then comparing the value with those given in AreaIMol runs where each of 
the above molecules had been deleted. 
 
It is possible that as more ‘free AMP’ is produced by the dissociation and subsequent breakdown 
of the lysyl-AMP intermediate AMP begins to compete with ATP for the active site. The ratio of 
AMP:ATP will rise as enzyme activity continues and so perhaps AMP is outcompeting ATP for the 
active site. To give an indication as to how tightly these free AMP molecules are bound, the 
program AreaIMol was used to calculate the solvent accessible surface area (SASA) buried in 
binding of these molecules compared to the SASA buried in binding of the AMP in the catalytic 
site. This is summarised in Table 17, which shows that there is almost double the surface area 
buried in substrate AMP binding when compared to free AMP binding. As expected due to its 
location on the external surface of the enzyme and as indicated by the LigPlot images, this 


















Figure 49: Active site of chain A in LAM_G4. 
This is the complete active site of chain A, including both ligands – lysine and 
AMP. Residues that hydrogen bond with either ligand are shown with carbons 









































The active site of chain A is seen in Figure 49, and that of chain B in Figure 50. In chain A, Glu478 
and Ile479 both form hydrogen bonds with both the 2’- and 3’-hydroxyls of the AMP molecule. In 
chain B, only Glu478 hydrogen bonds with both and Ile479 does so with just the 3’-hydroxyl. 
Bearing in mind that the position of the phosphate is the most contentious part of this model, in 
chain A Asn481 forms a hydrogen bond with the phosphate group whereas in chain B it is Arg306 
that does. That said, the phosphate group has been positioned as in other published structures 
with the nucleoside bent around into an approximate U-shape such that it is in an ideal position to 
attack the amino acid carboxylate. The adenine nucleobase pi-stacking with Phe318 seen in both 










Figure 50: Active site of chain B in LAM_G4. 
This is the complete active site of chain B, including both ligands, lysine and 
AMP. Residues that hydrogen bond with either ligand are shown with carbons 





























































Figure 51: LAM_G4, chain A ATP-binding site. 
This is a schematic of the ATP-binding site of LAM_G4 chain A, prepared using 
LigPlot. It shows the hydrogen bonds (green dotted lines) more clearly and provides 
information on residues/atoms involved in hydrophobic or VDW contacts (red 


























Figures 51 and 52 show that a number of residues are involved in hydrophobic or VDW contacts 
with the bound AMP ligands in each chain. These are summarised in the table below (Table 18) 
alongside those that contact the lysine substrate as described in figures 47 and 48 earlier. 
Figure 52: LAM_G4, chain B ATP-binding site. 
This is a schematic of the ATP-binding site of LAM_G4 chain B, prepared using 
LigPlot. It shows the hydrogen bonds (green dotted lines) more clearly and provides 
information on residues/atoms involved in hydrophobic or VDW contacts (red 
crescents) with the ligand. 
 
Table 18: Summary of hydrophobic or VDW contacts in LAM_G4 catalytic sites. 
This table lists the residues that are involved in hydrophobic or VDW contacts with the 




Figure 53: Active site comparison of LAM_G4 chain A and 3BJU chain A. 
This image shows the chain A active site of LAM_G4. Residues in LAM_G4 that 
hydrogen bond (yellow dashed line) with the ligands are shown in green. Also highlighted 
are those that hydrogen bond with the ligands in 3BJU (yellow) but not in LAM_G4 
(white). The density map belongs to LAM_G4, to show that there is little ambiguity in the 















Comparison with 3BJU 
In 3BJU, the structure of a tetrameric human lysyl-tRNA synthetase with ATP and lysine bound to 
each chain, the ribose forms hydrogen bonds with an adjacent Glu / Ile pair as well (positions 494 
and 495, respectively, in that structure) but the adenine ring also forms two hydrogen bonds with 
an asparagine residue (position 332 in 3BJU) of which the equivalent (position 315 in LAM_G4) is 
just slightly too far away in the LAM_G4 model. It is worth noting that in 3BJU the four different 
active sites do not have exactly the same non-covalent interactions with their ligands, indicating 
that there is some flexibility in the binding interaction. Figure 53 shows the chain A catalytic site of 
LAM_G4 again but this time also highlighting the residues that are involved in hydrogen bonding in 





















In Figure 53, it can be seen that most residues that hydrogen bond to the ligands in LAM_G4 also 
do so in 3BJU – but there are some differences. Firstly, there are residues that are just slightly too 
far away – Gly534 and Tyr483, both only 3.6 Å away – that could play a role in ligand binding but 
that do not in this model. The more significant differences are the comparatively larger distances 
between the phosphate group of AMP and Arg306 (4.2 Å) and Asn315 (4.8 Å). A limitation is that 
the positioning of the phosphate is potentially inaccurate given the lack of clear density, so the 




One major difference is that, as in LAM_H2, the Glu308 side chain is twisted away from the active 
site and is therefore unlikely to be involved in catalytic activity. This represents a major deviation 
between the mammalian and T. congolense enzymes. 
 
The second major deviation is, again, the position of Loop-Alpha. Loop-Alpha is in conformation 1 
in 3BJU, with Gly277 hydrogen bonding with the lysine, yet in LAM_G4, that loop is in 































Figure 54: Loop-Alpha comparison of LAM_G4 chain A and 3BJU chain A. 
This image shows the different conformation of Loop-Alpha in LAM_G4 compared to 
3BJU. 3BJU residues are shown with yellow carbons, with Gly277 and the lysine ligand in 
orange, whereas LAM_G4 residues have green carbons with Gly260 and the lysine 





Unlike the two previous structures that were produced from ATP-containing crystallisation 
experiments, LCM_F3 was produced using cordycepin, a nucleoside analogue, instead of ATP. 
The LCM_F3 crystal structure contains homodimeric LysRS1 with both active sites occupied by the 
potential inhibitor cordycepin. Figure 55 shows a cartoon rendering of the entire structure, featuring 





















In order to highlight any major structural differences between the monomers, Figure 56 shows the 










Figure 55: An overview of LCM_F3. 
This image shows an overview of the LCM_F3 structure. Chain A is in red and chain B is 
in blue, whereas the ligands are shown in magenta. The active sites are highlighted with 





LCM_F3 shows that this analogue is present in the active site with excellent representation in the 
electron density and therefore is likely to act, at least to some degree, as a competitive inhibitor to 
T. congolense lysyl-tRNA synthetase I.  
 
In chain A, Figure 57 shows Tyr324, Glu485, Tyr483 and Glu284 hydrogen bonding with lysine at 
the epsilon-amino group. Glu284 additionally forms a hydrogen bond with the alpha-amino group 
along with Glu322, whereas Asn481 and Arg306 both do so with the carboxyl group of the amino 
acid.  
 
Cordycepin can be seen to hydrogen bond with Arg537, Glu478 and Ile479 via the only hydroxyl  
group of its ribose moiety, and with Arg306 via a nitrogen group within the purine ring section.  
Figure 56: C-alpha trace overlay coloured by RMSD (LCM_F3_A v LCM_F3_B). 
This figure shows the C-alpha traces of chain A and chain B of LCM_F3. The overall 
RMSD for this alignment is 0.34. A PyMOL script was used to align the two and then 
colour them by local RMSD. A rainbow spectrum of colours indicates relative RMSD, 
starting at a dark blue for minimum RMSD ranging down to red for maximum RMSD. 
Grey indicates areas that were excluded from the alignment. Cordycepin is visible to 




Figure 57: The active site of LCM_F3 chain A. 
This image shows the ligands lysine and cordycepin, both coloured with magenta 























Figures 58 and 59 show this same area visualised in Ligplot so that the bonds can be more clearly 
seen, as well as to give an insight into which residues engage in hydrophobic or VDW contacts 















Figure 58: LCM_F3 chain A lysine-binding site in LigPlot. 
This is a schematic of the chain A lysine-binding site of LCM_F3, prepared using LigPlot. 
It shows the hydrogen bonds (green dotted lines) more clearly and provides information 





Figure 59: LCM_F3 chain A ATP-binding site in LigPlot. 
This is a schematic of the chain A ATP-binding site of LCM_F3, prepared using LigPlot. It 
shows the hydrogen bonds (green dotted lines) more clearly and provides information on 




































Figure 60: The active site of LCM_F3 chain B. 
This image shows the ligands lysine and cordycepin, both coloured with magenta 






















Figure 61: LCM_F3 chain B lysine-binding site in LigPlot. 
This is a schematic of the chain B lysine-binding site of LCM_F3, prepared using LigPlot. 
It shows the hydrogen bonds (green dotted lines) more clearly and provides information 




Chain B has the lysine ligand forming hydrogen bonds with Tyr324, Glu485, Tyr483 and Glu284 
again at the epsilon-amino group, with Glu284 and Glu322 hydrogen bonding to the alpha amino 
group. Asn481 is the only residue to hydrogen bond with the carboxyl group in this second chain. 



























Cordycepin forms hydrogen bonds with Ile479 and Glu478 via its lone ribose hydroxyl group and, 
unusually, His314 via the purine amino group. This hydrogen bond with His314 is not assigned by 
LigPlot. It is thought that, in principle, a (weak) hydrogen bond is possible due to the capability of 
aromatic rings to act as hydrogen bond acceptors. The nature of this bond remains unclear given 
that the crystal pH (6.5) is close to histidine pI (7.59), which will affect its strength. As this bond is 
not present in the chain A active site (due to His314 orientation), it is reasonable to assume that it 
is not required for cordycepin binding. 
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Figure 62: LCM_F3 chain B ATP-binding site in Ligplot. 
This is a schematic of the chain B ATP-binding site of LCM_F3, prepared using Ligplot. It 
shows the hydrogen bonds (green dotted lines) more clearly and provides information on 


















As expected, cordycepin binds in a similar fashion to the ATP that it is mimicking though with fewer 
non-covalent bonds. There are not as many hydrogen bonds, particularly because the cordycepin 
is lacking the additional hydroxyl group and the phosphates that should both form additional non-
covalent bonds. In addition to the hydrogen bonds already discussed, there are a number of 
residues involved in hydrophobic or VDW contacts with the bound ligands. These are summarised 














Figure 63: Cladosporin structure. 
 
 
Table 19: Summary of hydrophobic or VDW contacts in LCM_F3 catalytic sites. 
This table lists the residues that are involved in hydrophobic or VDW contacts with the 




Interestingly, there are no ‘free cordycepin’ molecules bound to either chain as there were in the 
other two structures at Tyr349. This may be because cordycepin does not have the 3’-hydroxyl 
group that forms the hydrogen bond with Tyr349, despite containing the ring that would enable pi-
stacking and, potentially, the hydrogen bond with Lys355.  
 
 
Comparison with 4YCU 
4YCU is a structure that shows cladosporin, another nucleoside analogue, in complex with the 
human LysRS. Although cladosporin is not as similar to cordycepin as cordycepin is to ATP, 
sharing only the ring structure and general dimensions that allow them to mimic ATP, they are 
being used for the same purpose: as competitive inhibitors that occupy the ATP-binding site to 
reduce aminoacyl-tRNA synthetase activity. Cladosporin has already been shown to target the 
LysRS of Plasmodium falciparum (Hoepfer et al., 2012), and so it may be useful to examine how 
cladosporin binds to the mammalian LysRS compared to how cordycepin binds to T. con LysRS1. 







In Figure 64, this comparison is visualised in PyMOL. It can be seen that cladosporin forms only 
three hydrogen bonds with the mammalian LysRS and that two of these involve the same residue 
Asn332. The equivalent residue Asn315 in LCM_F3 is slightly too far away from the cordycepin to 
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Figure 64: The active site of LCM_F3 showing residues of interest from 4YCU 
overlaid. 
LCM_F3 residues are coloured with green carbons and the cordycepin ligand is 
coloured with magenta carbons, whereas 4YCU residues are coloured with yellow 
carbons and cladosporin is coloured with orange carbons. Red residues are those 
that hydrogen bond with cladosporin in 4YCU but not with cordycepin in LCM_F3.  
Residue labels are set out in a [Residue]LCM_F3/4YCU format and underlined 



















form any similar hydrogen bonds. The other hydrogen bond between cladosporin and the enzyme 
in 4YCU is Glu325 where the equivalent in LCM_F3, Glu308, is one of the consistent differences 
observed in this study between mammalian and T.congolense LysRSes. As in all the others, 
Glu308 is twisted upward and so cannot bind to the ligand. Cladosporin is actually positioned 
differently within the 4YCU binding pocket compared to cordycepin in LCM_F3, which more closely 
imitates the natural ligands in terms of positioning, and this leads to substantial differences in 
hydrogen bonding between the two analogues. It indicates that, as expected, the most significant 
feature to retain when thinking of a molecule to bind to this site is the double-ring structure that 

























The underlined labels in Figure 64 indicate three residue positions that have been identified 
previously as determining specificity for cladosporin; in the mammalian LysRS, these are positions 
300, 321 and 337 (283, 304 and 320 in T. congolense LysRS1). The study from which 4YCU 
originates (Fang et al., 2015) explains that in other aaRSes examined, the equivalent residues 
either have larger or shorter side chains and cannot form stable interactions with cladosporin – in 
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this manner, they provide specificity to cladosporin binding. These three residues are said to be 
highly variable within and between different aaRS families which makes it unlikely for them to be 
important to the aminoacylation reaction. This can be seen in the figure above in that they are too 
far from cladosporin in 4YCU – and from cordycepin in LCM_F3 – to be directly involved in ligand 
binding interactions. This is important because it is a clear indication that residues not involved 
with the actual reaction can determine how specifically a proposed (or designed) inhibitor can bind 
to this pocket and affect this system. LigPlot was used to include hydrophobic or VDW contacts in 











Figure 65: ATP-binding sites of 4YCU chain A (left) and chain B (right). 
This is a schematic of both ATP-binding sites in 4YCU, prepared using Ligplot. It shows the 
hydrogen bonds (green dotted lines) more clearly and provides information on residues involved 




Table 21: SASA differences in 4YCU and LCM_F3 with regards to ATP-binding site. 
These were calculated by running AreaIMol on each structure to calculate solvent 
accessible surface area, then comparing the value with those given in AreaIMol runs 
where each of the above ligands had been deleted. 
 
Table 20: Summary of hydrophobic or VDW contacts in LCM_F3 and 4YCU ATP-binding 
sites. 
This table lists the residues that are involved in hydrophobic or VDW contacts with the ligands 
bound at the ATP-binding sites in both LCM_F3 and 4YCU. In the 4YCU rows, the equivalent 
LCM_F3 residues are shown in brackets. The bolded residues are the 4YCU residues involved 
whose equivalent LCM_F3 residues are also involved. 
 
 
Almost double the number of residues in 4YCU form hydrophobic or VDW contacts with 
cladosporin than residues in LCM_F3 do with cordycepin, but this is unsurprising given the relative 
sizes of the two ligands. Cladosporin is much larger due to containing three larger rings and 
therefore will be within range of more residues. Table 21 details the results of SASA calculations 
performed on these two structures in order to give some indication of how contacts might influence 
how tightly each ligand is bound in its respective structure. 
 
These results indicate that both ligands form similar total contact areas with their respective 
structures, which may suggest a similar strength of association. This is despite cladosporin forming 
more contacts with surrounding residues. It is likely that these additional contacts are simply a 
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Table 22: SASA differences in the ATP-binding sites of 3BJU, LAM_G4 and 
LCM_F3. 
These were calculated by running AreaIMol on each structure to calculate solvent 
accessible surface area, then comparing the value with those given in AreaIMol runs 
where each of the above molecules had been deleted.  
 
result of its larger size, therefore requiring more residues involved to achieve the same level of 
















Table 22 shows the SASA differences in the ATP-binding sites of chain A and chain B in structures 
3BJU, LAM_G4 and LCM_F3. Although roughly the same solvent-accessible surface area is 
buried in cordycepin binding as in cladosporin binding, there is notably more buried during AMP 
binding – and more again during the binding of ATP to mammalian LysRS in 3BJU. This is 
expected given that ATP is the ‘true’ binding ligand. AMP is not part of the lysyl-AMP intermediate 
has no role to play in the reaction other than being released. 
 
The next figures compare the chain of LAM_H2 containing the lysyl-AMP intermediate with 3BJU 






































Figure 66 is a visual comparison between the binding pockets of LCM_F3 and LAM_H2, showing 
the differences in the pockets – Arg537, Glu478, Asn481 and Asn315. Glu478 and Asn315 have 
been previously mentioned as catalytic residues in some structures, yet Asn481 and Arg537 have 
not been seen to form any direct contacts with substrates and therefore are unlikely to have direct 
influence on the aminoacylation reaction. These four residues show how the actual shape of the 
binding pocket itself changes when cordycepin binds and so could be worth comparing with bovine 
LysRS; if they are different, they could provide a way for cordycepin (or a similar, hypothetical 
designed drug) to distinguish between the parasite and host enzymes. Another comparison is 
made in Figure 67, but this time between 3BJU and LCM_F3, to indicate the differences between 
the mammalian and T. congolense enzyme sites. Also included in this figure is Glu308/325, as it is 





Figure 66: A comparison between the binding pockets of LCM_F3 and 
LAM_H2. 
LCM_F3 is shown with green carbons and a magenta ligand, whereas LAM_H2 is 
shown with yellow carbons and an orange ligand. The residues were identified 
through the use of the ‘surface map’ feature in PyMOL – all residues forming part of 













Figure 67: A comparison between the binding pockets of 3BJU and LCM_F3. 
3BJU is shown with green carbons, whereas LCM_F3 is shown with yellow carbons. 
The residues were identified through the use of the ‘surface map’ feature in PyMOL 
– all residues forming part of the surface exposed to the ligand were selected. 
Labelled residues are those with different positions. The ligands have been excluded 




































In Figure 68, another such comparison can be seen but this time with the surface maps of each 
pocket displayed. This enhances the difference that the conformation of Glu308/325 makes and is 
therefore very likely to be significant when it comes to specificity of any potential drugs to the T. 
congolense LysRS1 active site. An additional group stretching upward into that space, which is 
blocked off by Glu325 in the mammalian enzyme structure but made accessible by the absence of 
Glu308 there in the T. congolense enzyme structure, could potentially allow a molecule to bind to 




Figure 68: Differences in the binding pockets of 3BJU and LCM_F3. 
LCM_F3 is shown in the top image, whereas 3BJU is shown in the bottom one. Red 




































Mentioned earlier in this study, there is an unvalidated bovine LysRS sequence (F1MMK8) 
available on Uniprot. Because it is unreviewed, a very similar sequence – that of human LysRS – 
has been mainly used for comparisons. However, it stands to reason that the active site would be 
the most conserved part of any enzyme, and therefore between two sequences with high similarity 
overall they are very likely to be near identical. A homology model for bovine LysRS was prepared 
using the ‘SWISS-MODEL’ online resource and was briefly consulted to confirm that the glutamate 
at position 308 in the trypanosome sequence and position 325 in the human sequence is 
conserved in the bovine sequence at position 351. The homology model places it in the same 
conformation as the mammalian, as would be expected. However, at this stage the unreviewed 
bovine sequence is insufficiently validated to draw any major assertions other than showing that 




Conclusions & Future Directions 
Comparing all three of the structures solved in this study, as well as making comparisons with the 
two provided in the preceding study, allows for a comprehensive evaluation of which residues in 
the active site are involved in ligand binding. The RMSD values of the alignments between each of 
the structures in their entirety is summarised below in Table 23. 
 
 
These values are consistent with the comments made earlier in the text and with what is contained 
in each active site. For example, it makes sense that LCM_F3 (Cordycepin) and LAM_G4 (AMP) 
are more closely aligned than either of them with LAM_H2 (Intermediate) given the structural 
similarities between cordycepin and AMP. There are no major, consistent structural deviations in 
any of the structures solved in this report compared to the existing lysine-complexed structure, 
except for the loops already discussed. The largest alignment discrepancy as seen in this table is 
between the two chains of LAM_H2, but this is presumably just a result of this being the only 
structure with different active site contents in each chain (one chain containing the intermediate 
and the other containing lysine alone). This would be expected to have some impact on enzyme 






Table 23: Compiled alignment RMSD values. 





Residues identified that form hydrogen bonds with lysine, in chains that do not contain the inhibitor, 
are: Gly260 (part of Loop-Alpha), Glu284, Arg306, Glu322, Tyr324, Asn481, Glu485. With the 
exception of Gly260, which is only close enough to the lysine site in chain B of LAM_H2, these 
residues are seen to be involved in hydrogen bonding in every chain with the lysine substrate 
present – including with the lysine moiety of the lysyl-AMP intermediate in LAM_H2 chain A. In 
chains with the inhibitor cordycepin bound adjacent to lysine, Tyr483 is also seen to form a 
hydrogen bond with lysine – potentially suggesting that the presence of cordycepin does result in a 
slight adjustment of lysine position, but not one that seems significant. This is generally consistent 
with the findings of the preceding study, where T. congolense LysRS1 structures were solved with 
only one chain occupied by lysine and with both chains occupied by lysine. 
 
One major difference consistently mentioned through this report is the position of Gly260, which 
would hydrogen bond with lysine when the ‘Loop-Alpha’ is in conformation 1. Loop-Alpha is only 
observed to be in conformation 1 in the LAM_H2 chain B, which is the one chain of all those in this 
study that has only lysine bound. In three of the four chains of the structures previously studied, 
named ‘Semi-Complexed’ and ‘Fully-Complexed’, where lysine is bound alone without an adjacent 
ligand, Loop-Alpha is also in conformation 1. Evidently this loop is involved in a conformational 
change during enzyme activity that also affects the position of Loop-Beta, an external surface loop 
only really visualised – and only with weak density – when Loop-Alpha is in conformation 1. In this 
position, Loop-Beta occupies much of the space where Loop-Alpha resides in conformation 2, 
making it highly likely that the movement is linked and that Loop-Beta becomes more stable, 
therefore better defined in a crystal structure, when Loop-Alpha is in that conformation 1. 
 
In the one chain of the ‘Semi-Complexed’ structure where no ligands are bound, there is a lack of 
definitive electron density for Loop-Alpha suggesting that is conformationally flexible - though in 
that structure it has been arranged in a manner that is similar to conformation 2. It was initially 
suggested that that the binding of lysine stabilises this loop into an area where it can hydrogen 
bond with lysine. In view of the data observed in these newer structures, an updated explanation 
may be that the binding of a second ligand causes the reorganisation of that loop into an alternate 
conformation. This could be to promote tRNA binding, and thus trigger the second stage of the 
reaction where lysine is transferred from the lysyl-AMP intermediate onto tRNA and the resulting 
AMP is ejected. 
 
However, in the published human LysRS structure 3BJU, Loop-Alpha is seen in conformation 1 as 
well. This could be due to an evolutionary difference, as the human LysRS Loop-Alpha equivalent 
has a different sequence (PGGAVAKP compared to AGGAAARP). It could also be because the 
ATP in that structure has not yet been hydrolysed to AMP; this could drive the conformational 
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Table 24: Residues most commonly involved in hydrophobic or VDW contacts. 
This figure shows the residues at the ATP-binding site most often involved in hydrophobic 
or VDW contacts in the structures produced in this report. It is also stated whether those 
residues also form these contacts in the mammalian structures 3BJU and 4YCU. 
Residues already identified as forming hydrogen bonds with the ligands are not included.  
change of the loop. In the 6CHD structure, Loop-Alpha is also in conformation 1 and again, this 
could be because ATP has not actually been hydrolysed – this structure contains a lysyl-AMP 
intermediate analogue. It is difficult to draw a definitive conclusion using the data currently 
available, but this is an area that warrants further investigation in future studies. 
 
Moving onto the ATP binding site, residues identified that form hydrogen bonds with the second 
ligand are Arg306, Asn315, Glu478, Ile479, Asn481. Those seen to hydrogen bond with 
cordycepin are Arg306, His314, Glu478, Ile479 and Arg537. Of these, it is clear that Glu478 and 
Ile479 – along with Phe318 – are the most significant residues in this site. The former two 
hydrogen bond (Ile479 via its main chain carbonyl) with the hydroxyl groups present on the ribose 
moiety of AMP, cordycepin and the lysyl-AMP intermediate in these structures. That said, the fact 
that cladosporin can bind to the active site without possessing any such hydroxyl groups – and 
thus without hydrogen bonding with those two residues – indicates that it is possible for a molecule 
to bind without involving them directly, through the many hydrophobic or VDW contacts between 
site and ligand, so long as the ligand matches the complementary shape of the site. The latter 
residue mentioned, Phe318, is critical to the binding of the second ligand. Every structure 
determined with ligands in this site shows them to be pi-stacked with Phe318. It helps to correctly 
orientate the ligand and, in doing so, assists in ensuring that the ligand is positioned such that it 
can interact with other catalytic residues. Table 24 details the most common hydrophobic or VDW 
contacts in the (occupied) ATP-binding sites of the new structures resulting from this investigation, 
as reported by LigPlot. Note that residues already identified as involved in hydrogen bonding are 
excluded with the exception of His314, due to the lack of clarity surrounding the one instance in 






Table 24 indicates that residues Phe318 and Gly534 are very important to ligand binding through 
hydrophobic or VDW contacts, with His314 being of similar importance (though only capable of 
VDW contacts, formed by the non-polar areas of the sidechain with the ligand). 
 
Cordycepin has been identified as occupying the active sites of both chains in the LCM_F3 
structure and so, as mentioned earlier, can be considered to act at least in some capacity as a 
competitive inhibitor to this system. The SASA difference calculations seen in Table 21 provide 
some initial supporting information in that cordycepin binding results in buried SASA very similar to 
that of cladosporin. Buried solvent-accessible surface area may be linked to partial closure of the 
otherwise open active site, which would be reflective of competitive inhibition. As cladosporin is 
another nucleoside mimic, already shown to be capable of targeting the LysRS of another fly-
transmitted unicellular protozoan parasite (Plasmodium falciparum), this is a good sign. 
 
A major difference between the trypanosome and mammalian enzymes is the position of Glu308 
(325 in the human sequence). This is more unequivocal as it is easy to see that Glu308 is in a 
completely different orientation than its mammalian equivalent, twisted in the opposite direction 
and thus far from the active site in every single T. congolense LysRS1 structure but pointing 
toward the ATP-binding site and hydrogen bonding with the second ligand in every single 
mammalian structure examined. This means that there is increased volume in the parasitic 
enzyme ATP-binding site, as seen in the surface map view of this area in Figure 68 earlier, and 
ultimately this is the most obvious feature for exploitation when thinking of drug specificity. If a 
nucleoside analogue had a slightly larger group on the purine ring, perhaps a methyl or even an 
ethyl group, it may fit into the parasitic binding site whereas Glu325 will obstruct it from fitting into 
the mammalian binding site. 
 
However, as seen in the study on cladosporin specificity (Fang et al., 2015), it is not only the most 
obvious residues that can provide specificity.  In that study it was shown that in mammalian 
aaRSes three residues near to the active site but not directly involved in enzyme activity were 
responsible for the specificity cladosporin shows between and within aaRS families. 
 
Generally considered to be important for stabilisation of the phosphate groups in aminoacyl-tRNA 
synthetases, the metal ions in these structures have proven continually elusive. Within the active 
sites themselves, in no structure solved in this study has there been any density that resembles a 
magnesium ion but elsewhere in the structures – without consistency – there has been spherical 
density that has been successfully interpreted by the placement of these ions. The lack of 
magnesium ions in the active site could be a result of the lack of phosphate groups, in the 
structures LAM_G4 and LAM_H2 at least, suggesting that they may have already moved out of the 
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active sites with the hydrolysed inorganic pyrophosphate. In the structure 1E1T, the inorganic 
pyrophosphate can be seen slightly askew of the lysyl-AMP intermediate with magnesium ions 
beside it, presumably about to be ejected from the site. As for LCM_F3, it could be simply that 
magnesium is not required for the successful binding of cordycepin to the enzyme – cordycepin 
has no phosphate groups, after all. One potential method to home in on where the magnesium 
ions are located is described in the 1E1T publication (Onesti, 2000), where magnesium ions were 
substituted with electron-dense manganese ions in a crystallography experiment. 
 
Future directions 
There are various directions that this research can take in the future. Firstly, with regard to the 
LysRS1 explored in this study, other inhibitors such as cladribine (identified earlier and listed in 
Figure 6) could be trialled in crystallisation studies to explore how the differences in these 
molecules affects their binding to the site (if they bind at all). Inhibitor assays could be performed 
using cordycepin in order to determine its effectivity. If a conclusive ATP-bound LysRS1 structure 
is sought, using non-hydrolysable ATP will likely provide this quickly if the same experimental 
conditions are used. As mentioned previously, to accurately locate the magnesium ions a 
crystallography experiment could be run where the magnesium ions are substituted with 
manganese ions. 
 
Other aminoacyl-tRNA synthetase enzymes in T. congolense may also yield interesting results. It 
could be that there is a different aaRS that has even more significant differences between the 
parasitic and mammalian counterparts. Although time restraints prevented optimisation and 
diffraction analysis, as part of this study crystals have also been grown of T. congolense glycyl-
tRNA synthetase. These displayed a very different morphology to those of the lysyl-tRNA 





Figure 69: GlyRS + Glycine + ATP + MgCl2 (GAM) crystals. 
Sample solution consisted of 20mg/mL protein, 100mM glycine, 10mM ATP and 10mM MgCl2. 0.5μl 
of this was added to 0.5μl well (D8, PACT Premier) solution – 20% PEG 6K, 0.2M NH4Cl and 0.1M 
Tris pH8 buffer. Incubated at 4°C and inspected regularly.  
For the purposes of determining specificity of any potential inhibitors and to allow for more 
appropriate comparisons in the future, the structure of bovine LysRS enzyme (or the equivalent of 
whichever other aaRS is being studied) would be valuable and would eliminate the need for other 
mammalian structures as approximations between the host and parasite structures. As mentioned 
earlier, the sequence of this enzyme is unreviewed and so even confirming that would allow 
sequence analyses to definitively determine, for example, whether there is an equivalent of 
Glu308. From then, hopefully it could be expressed and then crystallised with different ligands, 
though of course this is not necessarily an easy feat.  
 
As climate change makes other areas of the world more habitable to these parasites, and 
globalisation aids their spread, the problem of Nagana is only going to worsen unless more 
pharmaceutical attention is paid to it. Hopefully the structures produced in this study, and the 
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